Entero Therapeutics (NASDAQ:ENTO) Stock Price Down 3.4% – What’s Next?

Entero Therapeutics, Inc. (NASDAQ:ENTO)’s share price traded down 3.4% on Thursday . The stock traded as low as $3.33 and last traded at $3.42. 23,477 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 2,798,922 shares. The stock had previously closed at $3.54.

Entero Therapeutics Price Performance

The company has a market cap of $5.43 million, a price-to-earnings ratio of -2.02 and a beta of 1.19. The firm has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $3.50.

Institutional Trading of Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC bought a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned about 0.74% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is currently owned by hedge funds and other institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.